Introduction
Pharmaceutical giant GlaxoSmithKline (GSK) has recently launched Shingrix, a breakthrough vaccine to protect against shingles (herpes zoster), in India. This development is especially significant for the country’s growing elderly population, which is at higher risk of shingles and its painful complication, post-herpetic neuralgia.
At Unnati Pharmax, we strive to keep our global partners informed about the latest medical advancements while ensuring seamless access to high-quality medicines and vaccines worldwide.
What is Shingles (Herpes Zoster)?
Shingles is caused by the reactivation of the varicella-zoster virus (VZV) — the same virus that causes chickenpox. Once a person recovers from chickenpox, the virus remains dormant in nerve cells and can reactivate later in life, particularly when the immune system weakens.
Symptoms of Shingles:
- Painful, blistering rash
- Burning or tingling sensations
- Fever, fatigue, and headache
- Risk of postherpetic neuralgia (PHN), a severe nerve pain that can persist for months or years
According to the Indian Council of Medical Research (ICMR), India sees approximately 4.5 million new cases of shingles annually, making prevention a public health priority.
Shingrix Vaccine: A Game Changer
Shingrix is a recombinant subunit vaccine that trains the immune system to produce antibodies against VZV.
Key Highlights:
- Two-dose schedule: The second dose is given 2–6 months after the first.
- High efficacy: Over 90% effectiveness in preventing shingles.
- Long-lasting protection: Provides extended immunity, even in older adults.
- Safety: Extensively tested in global clinical trials.
Why Shingrix Matters for India
- Elderly protection: India’s aging population is especially vulnerable.
- Reduced healthcare burden: Preventing shingles means fewer hospitalizations and lower long-term treatment costs.
- Improved quality of life: Preventing postherpetic neuralgia reduces chronic suffering.
- Global availability: Already approved in the U.S. and Europe (FDA press release).
Unnati Pharmax – Your Trusted Export Partner
As a global exporter of life-saving medicines and vaccines, Unnati Pharmax ensures that innovative treatments like Shingrix reach healthcare providers worldwide.
Why partner with us?
- Licensed under registered pharmacists
- WHO-GMP certified pharma supply chain
- Global bulk exports at competitive pricing
- Commitment to quality, safety, and timely delivery
👉 Learn more about our pharma exports and how we help deliver advanced healthcare worldwide.
Conclusion
The arrival of Shingrix in India marks a significant milestone in preventive healthcare. With its high efficacy and safety profile, Shingrix is expected to reduce the burden of shingles and protect millions of elderly individuals from pain and complications.
At Unnati Pharmax, we are dedicated to supporting global healthcare access through reliable medicine exports and timely updates on medical innovations.
👉 For bulk supply and export inquiries, contact Unnati Pharmax today.
FAQs
Q1: Who should take the Shingrix vaccine?
A: Adults aged 50 years and above, and those with weakened immunity, are strongly recommended to take Shingrix.
Q2: How many doses are required?
A: Two doses — the second is given 2–6 months after the first dose.
Q3: Is Shingrix better than older shingles vaccines?
A: Yes, clinical studies show Shingrix offers superior efficacy (>90%) compared to previous vaccines.
Q4: Can Unnati Pharmax export Shingrix internationally?
A: Yes, we facilitate global exports of vaccines and medicines, ensuring compliance with international regulations.
Add comment